Clearside IPO – $50 Million

Washington, DC – June 21, 2016 – Cooley advised Clearside Biomedical on its $50.4 million initial public offering. The company's common stock trades on the NASDAQ Global Market under the symbol "CLSD."

Cowen and Company and Stifel, Nicolaus & Company acted as joint book-running managers for the offering, and Needham & Company and Wedbush Securities acted as co-managers.

Clearside is a late-stage clinical biopharmaceutical company developing first-in-class drug therapies to treat blinding diseases of the eye. In addition to representing Clearside in the offering, Cooley has served as intellectual property counsel to the company since 2012.

The Cooley corporate and securities team included Brent Siler, Darren DeStefano, Brian Leaf, Katie Kazem, Mark Ballantyne and Jennifer Don.

About Cooley LLP

Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.

Cooley has 900 lawyers across 12 offices in the United States, China and Europe.

Related Contacts
Brent Siler  Senior Counsel Washington, DC, Reston
Darren DeStefano  Partner Reston
Brian Leaf  Partner Reston
Katie Kazem  Partner Reston
Mark Ballantyne  Partner Reston
Jennifer Don  Associate Reston
Michael Tuscan  Partner Washington, DC
Erik Milch  Partner Reston
Jeremy Binstock  Associate Reston
Natasha Leskovsek  Of Counsel Washington, DC
Phil Mitchell  Partner New York
Mark Windfeld-Hansen  Senior Counsel Palo Alto
Francis Wheeler  Partner Colorado